Your browser is no longer supported. Please, upgrade your browser.
CERC Cerecor Inc. monthly Stock Chart
Cerecor Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own0.40% Shs Outstand74.90M Perf Week9.57%
Market Cap187.16M Forward P/E- EPS next Y-0.46 Insider Trans- Shs Float70.45M Perf Month21.15%
Income-53.90M PEG- EPS next Q-0.12 Inst Own66.80% Short Float2.33% Perf Quarter-0.79%
Sales5.80M P/S32.27 EPS this Y64.30% Inst Trans1.77% Short Ratio5.92 Perf Half Y-14.86%
Book/sh0.51 P/B4.94 EPS next Y43.80% ROA- Target Price- Perf Year-29.41%
Cash/sh0.45 P/C5.60 EPS next 5Y- ROE- 52W Range1.52 - 6.19 Perf YTD-53.25%
Dividend- P/FCF- EPS past 5Y1.40% ROI-78.20% 52W High-59.29% Beta1.66
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin95.40% 52W Low65.79% ATR0.11
Employees18 Current Ratio2.50 Sales Q/Q-50.00% Oper. Margin- RSI (14)71.27 Volatility5.04% 5.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-161.30% Profit Margin- Rel Volume0.93 Prev Close2.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume277.50K Price2.52
Recom1.00 SMA2014.56% SMA509.53% SMA200-1.89% Volume257,417 Change4.13%
Mar-13-20Downgrade Maxim Group Buy → Hold
Jan-10-20Initiated Oppenheimer Outperform
Apr-09-19Initiated Maxim Group Buy $10
Apr-01-19Initiated H.C. Wainwright Buy $11
Dec-20-18Initiated Ladenburg Thalmann Buy
Dec-12-16Downgrade Rodman & Renshaw Buy → Neutral $4 → $1
Apr-13-16Initiated Rodman & Renshaw Buy $15
Dec-09-15Initiated Laidlaw Buy $10
Nov-27-20 12:17AM  
Nov-17-20 07:00AM  
Nov-16-20 07:10AM  
Nov-09-20 04:01PM  
Oct-26-20 11:55PM  
Oct-12-20 07:00AM  
Sep-10-20 07:00AM  
Aug-26-20 07:00AM  
Aug-13-20 09:00AM  
Aug-12-20 07:56AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Aug-04-20 07:00AM  
Aug-03-20 07:00AM  
Jul-21-20 07:00AM  
Jun-13-20 09:01AM  
Jun-12-20 11:42AM  
Jun-11-20 01:30PM  
Jun-10-20 04:18PM  
Jun-09-20 09:05AM  
Jun-08-20 04:01PM  
May-29-20 07:00AM  
May-28-20 07:00AM  
May-26-20 07:00AM  
May-13-20 06:00AM  
May-07-20 06:30AM  
May-04-20 09:15AM  
Apr-24-20 01:45PM  
Mar-27-20 09:39PM  
Mar-26-20 06:30AM  
Mar-19-20 08:50AM  
Mar-13-20 07:18AM  
Mar-11-20 06:30AM  
Mar-06-20 09:00AM  
Feb-04-20 01:31PM  
Feb-03-20 04:15PM  
Dec-23-19 10:26AM  
Dec-13-19 09:50AM  
Dec-10-19 03:20PM  
Dec-05-19 08:45AM  
Nov-14-19 06:30AM  
Nov-11-19 06:30AM  
Nov-04-19 06:30AM  
Oct-23-19 11:27AM  
Oct-14-19 06:30AM  
Aug-21-19 07:42AM  
Aug-08-19 04:05PM  
Jul-29-19 06:30AM  
Jul-25-19 03:22PM  
Jul-23-19 10:00AM  
Jul-15-19 06:30AM  
Jul-02-19 12:03PM  
Jul-01-19 06:30AM  
Jun-28-19 02:19PM  
Jun-12-19 04:05PM  
Jun-11-19 01:00PM  
May-13-19 02:00PM  
May-09-19 04:05PM  
Apr-29-19 10:38AM  
Apr-17-19 10:15AM  
Apr-15-19 06:30AM  
Apr-11-19 06:30AM  
Mar-26-19 10:30AM  
Mar-18-19 04:05PM  
Mar-06-19 06:05AM  
Mar-05-19 05:30PM  
Feb-22-19 10:11AM  
Feb-19-19 08:27AM  
Feb-15-19 06:30AM  
Jan-28-19 06:30AM  
Jan-22-19 06:30AM  
Jan-16-19 06:30AM  
Dec-13-18 07:00AM  
Nov-26-18 12:00PM  
Nov-22-18 02:13PM  
Nov-21-18 08:55AM  
Nov-13-18 07:00AM  
Oct-31-18 04:00PM  
Oct-30-18 04:00PM  
Oct-02-18 09:20AM  
Sep-26-18 01:00PM  
Sep-25-18 06:30AM  
Aug-31-18 02:46PM  
Aug-15-18 01:15PM  
Aug-09-18 06:30AM  
Aug-01-18 06:30AM  
Jul-31-18 01:37PM  
Jul-16-18 06:00AM  
Jul-12-18 02:00AM  
May-22-18 08:29AM  
May-19-18 10:02AM  
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLC10% OwnerNov 25Buy2.3915,00035,85030,114,285Nov 25 06:05 PM
ARMISTICE CAPITAL, LLC10% OwnerNov 24Buy2.4047,733114,55930,099,285Nov 25 06:05 PM
ARMISTICE CAPITAL, LLC10% OwnerNov 23Buy2.3237,26786,45930,051,552Nov 25 06:05 PM
ARMISTICE CAPITAL, LLCDirectorSep 04Buy2.20100,000220,00030,014,285Sep 09 06:57 PM
ARMISTICE CAPITAL, LLCDirectorJun 11Buy2.4428,00068,3201,128,000Jun 11 05:54 PM
Sullivan Christopher RyanInterim CFOJun 10Buy2.282,9546,7292,954Jun 11 09:08 PM
NEIL GARRY ARTHURChief Scientific OfficerJun 10Buy2.281,7994,09874,081Jun 11 09:02 PM
Harrell James Archie JrChief Commercial OfficerJun 10Buy2.286,39114,55928,009Jun 11 09:42 PM
COLA MICHAEL FChief Executive OfficerJun 09Buy2.50100,000250,000175,746Jun 11 08:28 PM
Harrell James Archie JrChief Commercial OfficerJun 09Buy2.5010,00025,00021,618Jun 11 09:42 PM
ARMISTICE CAPITAL, LLCDirectorJun 09Buy2.52267,806674,8711,100,000Jun 11 05:54 PM
ARMISTICE CAPITAL, LLCDirectorJun 09Buy2.501,753,6804,384,20029,914,285Jun 11 05:54 PM
Cerecor Inc.10% OwnerApr 15Sale1.5592,777144,0929,713,068Apr 27 09:30 AM
ARMISTICE CAPITAL, LLCDirectorApr 03Buy2.164,2809,245832,194Apr 07 04:59 PM
ARMISTICE CAPITAL, LLCDirectorMar 31Buy2.3326,61162,004827,914Mar 31 05:58 PM
ARMISTICE CAPITAL, LLCDirectorMar 30Buy2.3549,303115,862801,303Mar 31 05:58 PM
ARMISTICE CAPITAL, LLCDirectorMar 27Buy2.4336,00087,480752,000Mar 31 05:58 PM
ARMISTICE CAPITAL, LLCDirectorMar 23Buy2.521,3743,462716,000Mar 24 04:47 PM
ARMISTICE CAPITAL, LLCDirectorMar 20Buy2.509,62624,065714,626Mar 24 04:47 PM
ARMISTICE CAPITAL, LLCDirectorMar 19Buy2.601,5674,074705,000Mar 19 06:39 PM
ARMISTICE CAPITAL, LLCDirectorMar 18Buy1.9128,43354,307703,433Mar 19 06:39 PM
ARMISTICE CAPITAL, LLCDirectorMar 17Buy2.051,951,2193,999,99928,160,605Mar 19 06:39 PM
ARMISTICE CAPITAL, LLCDirectorFeb 03Buy3.98275,0001,094,500675,000Feb 05 05:43 PM
ARMISTICE CAPITAL, LLCDirectorFeb 03Buy3.98981,2823,905,50229,664,515Feb 05 05:43 PM
Calias PericlesChief Scientific OfficerDec 10Buy2.852,9138,29552,462Dec 11 04:15 PM
Miller Joseph MChief Financial OfficerDec 10Buy2.852,5987,39848,777Dec 11 04:41 PM
Harrell James Archie JrChief Commercial OfficerDec 10Buy2.853,0648,72511,618Dec 11 04:28 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.